Senstar Technologies Ltd. Q2 2026 Earnings Call Summary

Senstar Technologies Ltd. reported 8% year-over-year revenue growth in Q2 2026, driven by EMEA and APAC markets. The Blickfield acquisition contributed to a 100% year-over-year growth in LiDAR business, which now represents 20% of global sales. Management expects a U.S. corrections market recovery in the second half of 2026 and plans two major product launches in late Q3 2026. Cash reserves decreased to $8 million due to the Blickfield acquisition.

Original reporting
Published Aug 27, 2026, 4:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 4:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Senstar Technologies Ltd. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings release provides fresh guidance on R&D spend, product launches, and a recovery outlook for the U.S. corrections market.

02

Market read

First‑time disclosure of Q2 metrics and forward guidance offers traders new data for valuation and risk assessment.

03

What to watch

Potential government grant funding in Canada and Germany may offset R&D expenses.

Relevance 6/10Novelty 6/10Timing: post‑earnings Q2 2026

Background

Senstar Technologies reported Q2 2026 results, highlighting 8% YoY revenue growth, LiDAR expansion, and a cash decline after a €10.4 M acquisition.

Market effects

LiDAR growth may pressure competitors in security and thermal imaging markets.

Positive outlook for EMEA/APAC utilities and data‑center security spend.

Limited to niche security‑technology investors.

Counterpoint

Cash burn and declining U.S. revenue could signal liquidity risk despite LiDAR growth.

Key entities

  • Senstar Technologies Ltd.

    Security and LiDAR solutions provider.

  • Blickfield

    LiDAR business integrated into Senstar.

Related articles

$SNTMed

Senstar Technologies Corp (SNT): Financial results for Q3 2026

Senstar Technologies Corp (SNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Senstar Technologies Corporation 119 John Cavanaugh Drive T: +1-613-839-5572 Ottawa, ON Canada K0A 1L0 www.senstar.com Senstar Technologies Corporation Reports Third Quarter 2026 Financial Results U.S. market returns to growth with 23% revenue increase, EMEA and APAC

$SNTMed

Senstar Technologies Corp (SNT): Financial results for Q2 2026

Senstar Technologies Corp (SNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Senstar Technologies Corporation Reports Second Quarter 2026 Financial Results OTTAWA, ON, Aug. 25, 2026 /PRNewswire/ -- Senstar Technologies Corporation (NASDAQ: SNT), a leading international provider of comprehensive physical, video and access control security prod

$SNTHighAI 9/10

Senstar Technologies Q1 Earnings Call Highlights

Senstar Technologies reported a Q1 2026 loss as revenue fell to $8.1 million from $8.4 million a year earlier, citing project timing delays, longer procurement cycles and weaker U.S. government-related activity. CFO Alicia Kelly said EMEA revenue rose 43% (45% of total) while North America fell 20% and APAC fell 30%. Gross margin dropped to 60% from 67.2%; operating loss was $603,000. Management expects most delayed projects to convert in 2026.

$SNTHighAI 9/10

Senstar Technologies Corporation Reports First Quarter 2026 Financial Results

Senstar Technologies reported Q1 2026 results for the three months ended March 31, 2026. Revenue fell to $8.1 million from $8.4 million; gross margin declined to 60.0% from 67.2%. Net loss was $0.8 million versus net income of $1.0 million a year earlier. The company cited project timing delays and elongated procurement cycles, and noted Blickfeld acquisition on Feb. 13, 2026 affected results. Cash was $10.6 million (no debt).

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$NPCEMed

NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.